Published in Clin Trials on February 03, 2015
A post hoc evaluation of a sample size re-estimation in the Secondary Prevention of Small Subcortical Strokes study. Clin Trials (2016) 0.75
A conceptual model for the development process of confirmatory adaptive clinical trials within an emergency research network. Clin Trials (2017) 0.75
A simulation study of outcome adaptive randomization in multi-arm clinical trials. Clin Trials (2017) 0.75
The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov (2011) 7.57
Drug development and clinical trials--the path to an approved cancer drug. Nat Rev Clin Oncol (2012) 4.98
Outcome--adaptive randomization: is it useful? J Clin Oncol (2010) 4.81
Are outcome-adaptive allocation trials ethical? Clin Trials (2015) 4.68
Adaptive assignment versus balanced randomization in clinical trials: a decision analysis. Stat Med (1995) 2.70
Predictive biomarkers: a paradigm shift towards personalized cancer medicine. Nat Rev Clin Oncol (2011) 2.02
Bayesian adaptive randomization designs for targeted agent development. Clin Trials (2010) 1.74
Randomized phase II designs in cancer clinical trials: current status and future directions. J Clin Oncol (2005) 1.46
Simulation study for evaluating the performance of response-adaptive randomization. Contemp Clin Trials (2014) 1.45
Worth adapting? Revisiting the usefulness of outcome-adaptive randomization. Clin Cancer Res (2012) 1.33
Bayesian clinical trials in action. Stat Med (2012) 1.30
A comparison of Bayesian adaptive randomization and multi-stage designs for multi-arm clinical trials. Stat Med (2014) 1.12
Bayesian adaptive clinical trials: a dream for statisticians only? Stat Med (2011) 0.97
Adaptive randomization for clinical trials. J Biopharm Stat (2012) 0.97
Building efficient comparative effectiveness trials through adaptive designs, utility functions, and accrual rate optimization: finding the sweet spot. Stat Med (2015) 0.91
Clinical cancer research: the past, present and the future. Nat Rev Clin Oncol (2014) 0.87
Clinical trial designs for testing biomarker-based personalized therapies. Clin Trials (2012) 0.86
Statistical considerations for the next generation of clinical trials. Semin Oncol (2011) 0.82
Does the moral philosophy of the Belmont Report rest on a mistake? IRB (1987) 0.78